FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer

July 10, 2026 2:10 PM

Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) and Keytruda Qlex ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found